 If 2021 was a pivotal year for Context Therapeutics NASDAQ:CNTX Inc, 2022 promises to be even more so. Fresh from a US31.25 million fundraise and last Octobers debut on the Nasdaq, the clinical-stage biopharmaceutical company focused on bettering the lives of women living with cancer, is developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. 